News | August 08, 2022
Rossari Biotech Q1 FY23 revenue up 88%; Profit up 17%
Profit after Tax (PAT) was up 18% for Q1 FY23 to reach Rs. 28.7 crore whereas EBITDA was up 52% to reach Rs. 57.7 crore
Profit after Tax (PAT) was up 18% for Q1 FY23 to reach Rs. 28.7 crore whereas EBITDA was up 52% to reach Rs. 57.7 crore
With this expansion, the Grand Island site provides redundant capacity to support global supply of media and further extends the site’s capabilities to produce the high-quality technology and materials needed for the development and commercial manufacturing of vaccines and biologic therapies
Company will invest approximately ¥16 billion to increase production capacity by approximately 70% to ensure a stable supply
The safety profile of KEYTRUDA plus LENVIMA was consistent with previously reported data on the combination.
Lupin is the 6th largest company in the Indian Pharmaceutical Market
The WAVEsystem with the WAVEcontrol 4.0 embedded
Sandu Kumarvin is an Ayurvedic digestive and immunity booster for children and also offers several other benefits.
First and only PARP inhibitor to improve invasive disease-free survival, the primary endpoint, and overall survival, a key secondary endpoint, in these patients
The CSC shall hold Market Authorisation (MA) to sell SRL's BUSALFAN, API exclusively in China territory.
Under the PMBJP, till 30.06.2022, 8742 PMBJKs have been opened across the country including Government Hospitals and Government premises.
Subscribe To Our Newsletter & Stay Updated
